119 related articles for article (PubMed ID: 8280597)
1. The role of DNA topoisomerases II in drug resistance.
Alton PA; Harris AL
Br J Haematol; 1993 Oct; 85(2):241-5. PubMed ID: 8280597
[TBL] [Abstract][Full Text] [Related]
2. The role of topoisomerase II in drug resistance.
De Isabella P; Capranico G; Zunino F
Life Sci; 1991; 48(23):2195-205. PubMed ID: 1646358
[TBL] [Abstract][Full Text] [Related]
3. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
5. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
8. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells.
Ishikawa H; Kawano MM; Okada K; Tanaka H; Tanabe O; Sakai A; Asaoku H; Iwato K; Nobuyoshi M; Kuramoto A
Br J Haematol; 1993 Jan; 83(1):68-74. PubMed ID: 8094626
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II in multiple drug resistance.
Hofmann GA; Mattern MR
Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
[TBL] [Abstract][Full Text] [Related]
11. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors.
Khélifa T; Casabianca-Pignède MR; René B; Jacquemin-Sablon A
Mol Pharmacol; 1994 Aug; 46(2):323-8. PubMed ID: 8078494
[TBL] [Abstract][Full Text] [Related]
12. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
13. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
Beck WT
J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
[No Abstract] [Full Text] [Related]
14. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance associated with altered DNA topoisomerase II.
Beck WT; Danks MK; Wolverton JS; Kim R; Chen M
Adv Enzyme Regul; 1993; 33():113-27. PubMed ID: 8395133
[No Abstract] [Full Text] [Related]
16. The role of topoisomerase II alpha and beta in drug resistance.
Hochhauser D; Harris AL
Cancer Treat Rev; 1993 Apr; 19(2):181-94. PubMed ID: 8386983
[No Abstract] [Full Text] [Related]
17. Culprit and victim -- DNA topoisomerase II.
Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P
Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686
[TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]